![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Medicure Announces Full Patient Enrollment in MATCHED Clinical Trial
Medicure Announces Full Patient Enrollment in MATCHED Clinical Trial
Medicure, a cardiovascular drug discovery and development company, has reached full enrollment in its 120-patient advanced Phase II MATCHED trial evaluating MC-4232, in patients with co-existing diabetes and hypertension.
The results of the study are expected to be announced in the summer of 2005. Patients with co-existing diabetes and hypertension face a major increase in risk of cardiovascular complications, including heart attacks, stroke, heart failure and renal failure.
MC-4232 is a novel product that combines the cardioprotective properties of Medicure's lead product, MC-1, with an ACE inhibitor, an established first line therapy for blood pressure control.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct